The U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a cond...

Indian equities rallied sharply as an interim US-Iran peace framework eased geopolitical concerns and pushed oil prices lower. Improved inf...

Bitcoin hovered near $64,000, buoyed by falling oil prices and optimism for a US-Iran peace deal, which lifted overall risk sentiment. Whil...

Indian markets saw volatility and closed lower on Wednesday. Key companies are in focus due to significant developments. SoftBank reduced i...

Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...

Market expert Sudip Bandyopadhyay outlines investment strategies across key sectors. He sees opportunities in State Bank of India and a gen...

Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...

Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...

Bajaj Auto has announced that its board will consider a share buyback proposal on May 6, 2026, signalling plans to return surplus cash to s...

The land parcel, expected to fetch about ₹3,400 crore for AstraZeneca Pharma India, has drawn interest from developers including the Sattva...

The Hyderabad-based promoter family of V Ramprasad Reddy and K Nityanand Reddy currently own 51.8% of Aurobindo, a vertically integrated ph...

On Wednesday, shares of Aurobindo closed 4.8 per cent lower at Rs 450.75 on the BSE.

The acquired business has been carved out by the management of Sandoz for divestment.

The acquisition will add approximately 300 products including projects in development as well as commercial and manufacturing capabilities ...

Plethico USA had not fulfilled obligations while selling Natrol to Aurobindo Pharma USA, hence they have to pay a penalty.

Under the Scheme of Arrangement, Aurobindo would transfer its injectables Unit IV to Curepro, and the same is to be effective from April 1,...

Aurobindo Pharma has entered into a strategic deal with TAD Italy, for acquisition of intellectual property and marketing authorizations.